| 1. |
|
|
| 2. |
- Barucci, M. A., et al.
(author)
-
Detection of exposed H2O ice on the nucleus of comet 67P/Churyumov-Gerasimenko as observed by Rosetta OSIRIS and VIRTIS instruments
- 2016
-
In: Astronomy and Astrophysics. - : EDP Sciences. - 0004-6361 .- 1432-0746. ; 595
-
Journal article (peer-reviewed)abstract
- Context. Since the orbital insertion of the Rosetta spacecraft, comet 67P/Churyumov-Gerasimenko (67P) has been mapped by OSIRIS camera and VIRTIS spectro-imager, producing a huge quantity of images and spectra of the comet's nucleus. Aims. The aim of this work is to search for the presence of H2O on the nucleus which, in general, appears very dark and rich in dehydrated organic material. After selecting images of the bright spots which could be good candidates to search for H2O ice, taken at high resolution by OSIRIS, we check for spectral cubes of the selected coordinates to identify these spots observed by VIRTIS. Methods. The selected OSIRIS images were processed with the OSIRIS standard pipeline and corrected for the illumination conditions for each pixel using the Lommel-Seeliger disk law. The spots with higher I/F were selected and then analysed spectrophotometrically and compared with the surrounding area. We selected 13 spots as good targets to be analysed by VIRTIS to search for the 2 mu m absorption band of water ice in the VIRTIS spectral cubes. Results. Out of the 13 selected bright spots, eight of them present positive H2O ice detection on the VIRTIS data. A spectral analysis was performed and the approximate temperature of each spot was computed. The H2O ice content was confirmed by modeling the spectra with mixing (areal and intimate) of H2O ice and dark terrain, using Hapke's radiative transfer modeling. We also present a detailed analysis of the detected spots.
|
|
| 3. |
- Pfaller, M.A., et al.
(author)
-
Twelve years of fluconazole in clinical practice : Global-trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida
- 2004
-
In: Clinical Microbiology and Infection. - : Elsevier BV. - 1198-743X .- 1469-0691. ; 10:SUPPL. 1, s. 11-23
-
Journal article (peer-reviewed)abstract
- We determined the species distribution and in-vitro susceptibility of 6082 bloodstream infection (BSI) isolates of Candida spp. collected from 250 medical centres in 32 nations over a 10-year period from 1992 through 2001. The species included 3401 C. albicans, 984 C. glabrata, 796 C. parapsilosis, 585 C. tropicalis, 153 C. krusei, 67 C. lusitaniae, 48 C. guilliermondii, 10 C. famata, 10 C. kefyr, six C. pelliculosa, five C. rugosa, four C. lipolytica, three C. dubliniensis, three C. inconspicua, two C. sake and one isolate each of C. lambica, C. norvegensis and C. zeylanoides. Minimum inhibitory concentration determinations were made using the National Committee for Clinical Laboratory Standards reference broth microdilution method. Variation in the rank order and frequency of the different species of Candida was observed over time and by geographic area. The proportion of BSI due to C. albicans and C. glabrata increased and C. parapsilosis decreased over time in Canada, the USA and Europe. C. glabrata was an infrequent cause of BSI in Latin America and the Asia-Pacific region. Very little variation in fluconazole susceptibility was observed among isolates of C. albicans, C. tropicalis and C. parapsilosis. These species accounted for 78% of all BSI and remained highly susceptible (91-100% susceptible) to fluconazole from 1992 to 2001 irrespective of geographic origin. The prevalence of fluconazole resistance among C. glabrata isolates was variable both over time and among the various countries and regions. Resistance to fluconazole among C. glabrata isolates was greatest in the USA and varied by US census region (range 0-23%). These observations are generally encouraging relative to the sustained usefulness of fluconazole as a systemically active antifungal agent for the treatment of candida BSI. © 2004 Copyright by the European Society of Clinical Microbiology and Infectious Diseases.
|
|
| 4. |
|
|
